PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGFβ1 responses
Chu-Han Feng, Linda Peltier, Tiffanie Chouleur, Milea DiPonzio, Isabelle Aubry, Alexandre J Poirier, Zuzet M Cordova, Yunyun Shen, Sébastien Tabariès, Xiaona Cao, Guojun Chen, Andreas Bikfalvi, Silvia M Vidal, Peter M Siegel, Pierre Laneuville, Michel L Tremblay · 2026
Read PTPN1/PTPN2 inhibition improves NK cancer therapy by enhancing IL-2 and mitigating TGFβ1 responses by Chu-Han Feng, Linda Peltier, Tiffanie Chouleur, Milea DiPonzio, Isabelle Aubry, Alexandre J Poirier, Zuzet M Cordova, Yunyun Shen, Sébastien Tabariès, Xiaona Cao, Guojun Chen, Andreas Bikfalvi, Silvia M Vidal, Peter M Siegel, Pierre Laneuville, Michel L Tremblay (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13219468.txt.
Description
Natural killer (NK) cells are promising candidates for allogeneic anti-cancer immunotherapy. However, their cytolytic activity is often suppressed by the tumor microenvironment. We demonstrate that genetic silencing or pharmacological dual inhibition of protein tyrosine phosphatases PTPN1 and PTPN2 (PTPN1/N2) in NK cells significantly enhances anti-tumor cytolytic activity both in vitro and in vivo.
Catalog record
| CREATOR | Chu-Han Feng, Linda Peltier, Tiffanie Chouleur, Milea DiPonzio, Isabelle Aubry, Alexandre J Poirier, Zuzet M Cordova, Yunyun Shen, Sébastien Tabariès, Xiaona Cao, Guojun Chen, Andreas Bikfalvi, Silvia M Vidal, Peter M Siegel, Pierre Laneuville, Michel L Tremblay |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 101 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |